News fro Lymphoma Oral Sessions

Abstract 7500 Oral Abstract Session, Sun, 9:45 AM-12:45 PM

RELEVANCE: Phase III randomized study of lenalidomide plus rituximab (R2) versus chemotherapy plus rituximab, followed by rituximab maintenance, in patients with previously untreated follicular lymphoma. First Author: Nathan Hale Fowler, The University of Texas MD Anderson Cancer Center, Houston, TX

Conclusions: In the first randomized phase III comparison of a chemo-free regimen vs standard R-chemo followed by rituximab maintenance in previously untreated FL, R2 showed similar efficacy and a different safety profile to R-chemo. Clinical trial information: NCT01650701

See also Report in the ASCO Daily News

Abstract 7505 Oral Abstract Session, Sun, 9:45 AM-12:45 PM

Updated safety and long term clinical outcomes in TRANSCEND NHL 001, pivotal trial of lisocabtagene maraleucel (JCAR017) in R/R aggressive NHL.  First Author: Jeremy S. Abramson, Massachusetts General Hospital Cancer Center, Boston, MA

Conclusions: Liso-cel shows durable responses in pts with heavily pretreated R/R DLBCL and trends toward more durable responses at DL2. Observed acute toxicities have been manageable at all DLs tested and long-term safety from the nonpivotal cohort will be reported. Clinical trial information: NCT02631044